Clinical trials: Pediatric Medulloblastoma, active
Brain Tumor, Pediatric, Medulloblastoma, Childhood
GD2-CAR T Cells for Pediatric Brain Tumours
The purpose of this study is to test the safety and efficacy of iC9-GD2-CAR T-cells, a third generation (4.1BB-CD28) CAR T cell treatment targeting GD2 in paediatric or young adult patients affected by relapsed/refractory…
- Conditions
- Brain Tumor, Pediatric, Medulloblastoma, Childhood, Embryonal Tumor, High Grade Glioma
- Trial name
- NCT05298995
- Testing
- GD2-CART01 (iC9-GD2-CAR T-cells)
- Where
- Italy
- Volunteers
- 54 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Recurrent Medulloblastoma, Recurrent Ependymoma
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
A Phase 2 study investigating the addition of cRIT 131I-omburtamab to irinotecan, temozolomide, and bevacizumab for patients with recurrent medulloblastoma.
- Trial name
- NCT04743661
- Testing
- Irinotecan, Temozolomide, Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- Pediatric Brain Tumor Consortium
Brain Tumors
International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
The study PNET 5 MB has been designed for children with medulloblastoma of standard risk (according to the risk-group definitions which have been used so far; e.g. in PNET 4).
- Trial name
- NCT02066220
- Testing
- Radiotherapy without Carboplatin, Reduced-intensity maintenance chemotherapy, Radiotherapy with Carboplatin
- Where
- 77 sites in Austria, Belgium and 14 more
- Volunteers
- 360 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
There is a significant unmet medical need for effective therapies for pediatric relapsed/refractory solid tumors. EGFR is highly and stably expressed in multiple pediatric solid tumor subtypes, and adult Phase I data of Becotatug…
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma, Lymphoepithelial Carcinoma, Rhabdomyosarcoma
- Trial name
- MRG003 (NCT07584499)
- Testing
- Becotatug Vedotin
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a…
- Conditions
- Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma
- Trial name
- NCT04284774
- Testing
- Tipifarnib
- Where
- 172 sites in United States, Puerto Rico
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Pediatric Central Nervous System Tumors, Medulloblastoma
Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors
his is a single-center, prospective observational study in children and adolescents with central nervous system tumors who need whole-brain and whole-spine radiation therapy (craniospinal irradiation, CSI).
- Conditions
- Pediatric Central Nervous System Tumors, Medulloblastoma, Germinoma, Ependymoma
- Trial name
- VBS-CSI-PT-PED (NCT07589361)
- Testing
- Vertebral Body-Sparing Craniospinal Proton Irradiation
- Volunteers
- 38 people
- Sponsor
- Ruijin Hospital
Solid Tumors, CNS Tumors
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain…
- Trial name
- STARTRK-NG (NCT02650401)
- Testing
- Entrectinib
- Where
- 26 sites in United States, Canada and 7 more
- Volunteers
- 69 people
- Sponsor
- Hoffmann-La Roche
Brain and Central Nervous System Tumors
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
RATIONALE: In this study a combination of anti-cancer drugs (chemotherapy) is used to treat brain tumors in young children. Using chemotherapy gives the brain more time to develop before radiation is given.
- Trial name
- NCT00602667
- Testing
- Induction Chemotherapy, Low-Risk Therapy, High-Risk Therapy
- Where
- 6 sites in United States, Australia
- Volunteers
- 293 people
- Sponsor
- St. Jude Children's Research Hospital
Childhood Medulloblastoma
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain.
- Trial name
- NCT05382338
- Testing
- Audiometric Test, Auditory Brainstem Response, Biospecimen Collection
- Where
- 111 sites in United States, Canada
- Volunteers
- 225 people
- Sponsor
- Children's Oncology Group
Medulloblastoma, Ependymoma
Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma
It is an open multicentric phase I/II trial with axitinib (Inlyta®) and metronomic delivery of etoposide for children, adolescent and young adults (AYA) with refractory/ relapsing solid tumors.
- Trial name
- MEPENDAX (NCT06485908)
- Testing
- administration of axitinib in combination with etoposide
- Volunteers
- 40 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Solid Tumors, Neuroblastoma
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
A pilot pharmacokinetic trial to determine the safety and efficacy of a flavored, orally administered irinotecan VAL-413 (Orotecan®) given with temozolomide for treatment of recurrent pediatric solid tumors including but not…
- Conditions
- Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma
- Trial name
- NCT04337177
- Testing
- VAL-413, Temozolomide
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- Valent Technologies, LLC
Neoplasms, Brain, Glioblastoma Multiforme
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor.
- Conditions
- Neoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum, Neoplasms
- Trial name
- NCT03911388
- Testing
- G207
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Medulloblastoma, Refractory Medulloblastoma
A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)
The purpose of this study is to find out whether 177Lu-DPTA-omburtamab is a safe treatment for children and adolescents with recurrent/refractory medulloblastoma or another type of cancer with CNS metastases.
- Conditions
- Recurrent Medulloblastoma, Refractory Medulloblastoma, CNS Metastases, Central Nervous System Metastasis
- Trial name
- NCT07698899
- Testing
- 25 mCi 177Lu- DTPA-omburtamab
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
This phase II Pediatric MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma
- Trial name
- NCT03155620
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy
- Where
- 172 sites in United States, Australia and 2 more
- Volunteers
- 1,377 people
- Sponsor
- National Cancer Institute (NCI)
Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3-specific chimeric antigen receptor (CAR) and EGFRt.
- Conditions
- Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Ependymoma
- Trial name
- NCT04185038
- Testing
- SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Seattle Children's Hospital
Advanced Malignant Solid Neoplasm, Recurrent Ependymoma
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well larotrectinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions that may have spread from where it first started to…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Glioma
- Trial name
- NCT03213704
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan
- Where
- 124 sites in United States, Puerto Rico
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Medulloblastoma Tumor
Evaluation of The Radioprotective Effect of 3D-Printed Intraoral Stents in Children With Brain Cancer.
Brain cancer patients undergoing radiotherapy may experience oral complications such as oral mucositis, gingival inflammation, plaque accumulation, radiation-induced caries, and reduced oral-health-related quality of life due to…
- Trial name
- NCT07715357
- Testing
- 3D printed intraoral stents.
- Volunteers
- 72 people
- Sponsor
- Ain Shams University
Medulloblastoma, Central Nervous System Embryonal Tumor
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
This is a single-site, open-label Phase I treatment study evaluating the manufacturing feasibility and safety of chimeric antigen receptor (CAR) T cells targeting the oncofetal protein Glypican-2 (GPC2) in pediatric and young…
- Conditions
- Medulloblastoma, Central Nervous System Embryonal Tumor, Refractory Medulloblastoma, Recurrent Medulloblastoma
- Trial name
- NCT07087002
- Testing
- GPC2-CAR T cells, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Stanford University
Medulloblastoma
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
- Trial name
- NCT05535166
- Testing
- Surgical resection, Ommaya/VPS, Methotrexate
- Where
- 10 sites in United States
- Volunteers
- 130 people
- Sponsor
- St. Jude Children's Research Hospital
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine…
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma
- Trial name
- NCT05096481
- Testing
- PEP-CMV, Temozolomide, Tetanus Diphtheria Vaccine
- Where
- 13 sites in United States
- Volunteers
- 120 people
- Sponsor
- Nationwide Children's Hospital